#Iceland #Reykjavik #Metabolomics #ADHD Therapy #3Z Pharmaceuticals

3Z Pharmaceuticals Unveils Groundbreaking Study on ADHD

3Z Pharmaceuticals, a company specializing in therapeutics for central nervous system (CNS) disorders, has made headlines with its recent publication in The Journal of Pharmacology and Experimental Therapeutics. This pivotal study presents new findings on the metabolic mechanisms associated with ADHD treatments. By utilizing advanced untargeted metabolomic and lipidomic profiling, the research seeks to fill a crucial gap in our understanding of how ADHD medications work.

The Relevance of ADHD

ADHD or Attention Deficit Hyperactivity Disorder is one of the most prevalent neurodevelopmental disorders, afflicting millions worldwide. As treatment options remain limited and the underlying mechanisms complex, the need for innovative approaches and insights is more critical than ever.

Key Insights from the Study

According to Dr. Karl Karlsson, CEO of 3Z Pharmaceuticals, the recent study is a significant step forward in comprehending the intricacies of ADHD therapeutics. The findings revealed a convergence of metabolic pathways across both stimulant and non-stimulant ADHD medications, bolstering the company’s previously announced identification of amlodipine as a potential L-type calcium channel blocker candidate.

Main Findings Include:

1. Metabolic Pathway Convergence: The study shows that commonly used ADHD medications, including methylphenidate, guanfacine, and atomoxetine, along with the novel amlodipine, share metabolic pathways related to amino acid and lipid processing. This includes pathways linked to glycine, serine, threonine, lysophosphatidylcholine, and sphingomyelin.

2. Systemic Impact: Instead of working through unconnected mechanisms, ADHD therapies exert a wider, systemic influence on neurotransmitter precursors, markers of oxidative stress, and energy metabolism. This holistic interaction opens up avenues for better therapeutic strategies.

3. Amlodipine's Overlapping Effects: The metabolic profiling indicated that amlodipine closely parallels established ADHD treatments, emphasizing its potential as a therapeutic pathway for ADHD management.

Innovative Approach

To conduct this research, 3Z Pharmaceuticals employed an advanced systems biology approach. This method combined cross-species analysis using a zebrafish model for ADHD with tailored metabolomic profiling to investigate common pathways between the investigated drugs. This meticulous study design not only validates the company's drug discovery platform but also lays groundwork for future explorations into ADHD treatment innovations.

Future Directions

Building on these pivotal findings, 3Z Pharmaceuticals is keen to further its metabolomics-driven CNS drug discovery strategies. The aim is twofold: refining therapeutic targets and optimizing treatment strategies to enhance clinical outcomes as they move towards future clinical developments.

About 3Z Pharmaceuticals

Based in Reykjavik, Iceland, 3Z Pharmaceuticals is committed to identifying and advancing innovative therapies for CNS disorders. Their cutting-edge drug development platform integrates high-throughput screening, multi-omics analyses, and AI-driven analytics. The company emphasizes translational validation, which de-risks CNS drug development while enhancing predictability through multifaceted assessments, including human Mendelian randomization and genetic studies.

For media inquiries or further information, contact Karl Karlsson, CEO at 3Z Pharmaceuticals.

Conclusion

The implications of this study are profound, marking a potential turning point in how ADHD is understood and treated. As 3Z Pharmaceuticals continues to innovate and explore new avenues, the hope for patients suffering from ADHD grows brighter.